|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
MV-associated TF-activity was low in controls and in ITP patients before and after initiation of TPO-RA-treatment.
|
31280643 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with TPO-RAs resulted in changes in six miRNAs including miR-199a-5p (p = 0.001), miR-33a-5p (p = 0.003), miR-382-5p (p = 0.004), miR-92b-3p (p = 0.005), miR-26a-5p (p = 0.008) and miR-221-3p (p = 0.023); while miR-195-5p remained unchanged and significantly higher than in controls, despite the increase in the platelet count, which may indicate its possible role in the pathophysiology of ITP.
|
30885035 |
2020 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR).
|
31723222 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future head-to-head trials including TPO-RAs vs. RTX or Eltrombopag vs. Romiplostim are necessary to validate our study findings and determine the most suitable therapy for persistent/chronic ITP.
|
30507320 |
2019 |
|
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Integrated network pharmacology and metabolomics analysis of the therapeutic effects of ZDF on ITP may be as follows: ZDF counteracts ITP symptoms mainly by inhibiting Ras/MAPKs (Ras/Mitogen-activated protein kinases) pathway, and the expression of upstream protein (Ras) and downstream protein (p-ERK, p-JNK, p-p38) were inhibited, which affects the content of effect index associated with proliferation (Thrombopoietin, TPO; Granulocyte-macrophage colony stimulating factor, GM-CSF), inflammation (Tumor necrosis factor-α, TNF-α; Interleukin-6, IL-6), immune (Interleukin-2, IL-2; Interferon-gamma, IFN-γ; Interleukin-4, IL-4), so that the body's arginine, Δ<sup>12</sup>-prostaglandin j2 (Δ<sup>12</sup>-PGJ2), 9-<i>cis</i>-Retinoic Acid, sphingosine-1-phosphate (S1P), oleic acid amide and other 12 endogenous metabolites significantly changes.
|
29971001 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using an inhibition step with excess TPO in fluid-phase to improve binding specificity, the prevalence of anti-TPO autoantibodies was: active ITP: 9/32 (28%); remission ITP: 0/14 (0%); non-immune thrombocytopenias: 1/10 (10%); and healthy controls: 1/11 (9%).
|
29532903 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
: Thrombopoietin receptor agonist (TPO-RAs) have demonstrated good efficacy and tolerance in clinical trials in refractory chronic primary immune thrombocytopenia (ITP) or chronic ITP with contraindication for splenectomy.
|
29738335 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We included 18 patients with SLE-ITP treated with TPO-RAs; 10 (55%) had aPL, 5 (27%) showing definite APS.
|
29757439 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RCTs comparing the TPO-RAs with placebo in adult ITP were included.
|
29856837 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequential use of the TPO-RAs romiplostim and eltrombopag in ITP patients failing either agent was retrospectively evaluated to assess efficacy and impact of clinical characteristics on outcome.
|
28983953 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Median time to splenectomy from diagnosis of ITP was 25 months in the group of patients pretreated with TPO-RAs vs 14.5 months in the group of splenectomized patients.
|
29243329 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, TPO levels predict response to eltrombopag and romiplostim in ITP patients, with lower levels predicting improved probability and magnitude of response.
|
30187942 |
2018 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study might improve our understanding of the mechanism of action of TPO-RAs and provide important information for optimizing therapeutic strategies for ITP.
|
28142109 |
2017 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seventy-five apparently healthy children were enrolled as control group. aTPo and aTg antibodies were significantly higher and more frequently positive in all children with ITP and in each ITP group than the control group (P <.05 in all).
|
29190168 |
2017 |
|
Immune thrombocytopenic purpura
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effect of TPO-RAs on inflammatory cytokine production in ITP patients has not been well investigated.
|
27819522 |
2017 |